Details for Patent: 11,787,782
✉ Email this page to a colleague
Which drugs does patent 11,787,782 protect, and when does it expire?
Patent 11,787,782 protects TRYVIO and is included in one NDA.
This patent has seventy-four patent family members in twenty-nine countries.
Summary for Patent: 11,787,782
| Title: | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
| Abstract: | The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and its use as endothelin receptor antagonist, in combination with other active ingredients or therapeutic agents including an angiotenin receptor blocker, and/or a calcium channel blocker, and preferably a diuretic which is a thiazide-like diuretic, in the prophylaxis or treatment of certain endothelin related diseases. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said other active ingredients or therapeutic agents. The invention further relates to such pharmaceutical compositions comprising novel crystalline forms of aprocitentan. |
| Inventor(s): | Marc BELLET, Martin Bolli, Martine Clozel, Marc IGLARZ |
| Assignee: | Actelion Pharmaceuticals Ltd , Idorsia Pharmaceuticals Ltd |
| Application Number: | US17/472,349 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,787,782
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686-001 | Mar 19, 2024 | RX | Yes | Yes | 11,787,782 | ⤷ Start Trial | TREATMENT OF HYPERTENSION IN COMBINATION WITH OTHER ANTIHYPERTENSIVE DRUGS, INCLUDING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER DRUGS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,787,782
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017400276 | ⤷ Start Trial | |||
| Australia | 2018225309 | ⤷ Start Trial | |||
| Brazil | 112019017644 | ⤷ Start Trial | |||
| Brazil | 112019017658 | ⤷ Start Trial | |||
| Canada | 3053991 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
